Epilepsy News Around the World
News articles of interest will be linked here for a period of time. Submit news articles to .
Art Competition to celebrate International Epilepsy Day 2017 â€“ Monday 13th February
This competition is open to everyone! All are encouraged to take part in this great event so that, together, we can raise awareness about epilepsy on International Epilepsy Day.
Prizes: Under 12 years: 1st place US$500; 2 runners-up of US$250 each. Over 12 years: 1st place US$500; 2 runners-up of US$250 each. In addition, all entries received will be placed in a gallery on the Epilepsy Day website | Competition rules | Entry form
Opportunity for high-level epilepsy experts to join an important EU Working Group and influence epilepsy research funding
The European Commission offers an opportunity to have a concrete influence on the direction of EU research policies by inviting those interested to apply to the High Level Group on maximizing the impact of EU Research and Innovation programmes. The group will be formed with regard to an interim evaluation of Horizon 2020 that the Commission is planning to carry out by the end of 2017. The Commission will invite a High Level Group of personalities and authoritative experts to draw strategic conclusions on maximising the impact of EU Research and Innovation programmes in the future and formulate a vision for future EU Research and Innovation.
This presents a genuine opportunity for the brain space to get actively involved in shaping not only the evaluation of Horizon 2020, but also the direction of the H2020 successor — the shape of the next EU Framework Programme will be closely related to the evaluation of H2020.
The ILAE has been informed that GlaxoSmithKline has made the decision to discontinue Trobalt/Potiga (retigabine/ezogabine) from all markets in which the product is currently still available. This decision has been reached based on the very limited usage of the medicine in patients with epilepsy and the continued decline in new patient initiation. The decision has not been driven by the identification of a new safety issue, or the conclusion that the risk/benefit of the product is no longer acceptable in its licensed indication. Trobalt/Potiga will remain available to existing epilepsy patients until the end of June 2017 to enable identification of an appropriate alternative where required, after which the license will be withdrawn. In the meantime HCPs are being advised to start transitioning their patients off the medicine. More information about discontinuation …
Epilepsy League supports innovative research project English
Prof. Jean-Marc Fritschy and Tilo Gschwind of the University of Zurich have been awarded this year‘s Research Grant of CHF 25,000 by the Swiss League Against Epilepsy. With the help of innovative optogenetics, the researchers are investigating the development of epilepsy and paving the way for new treatment methods.
Two awards open to bidding:
The Michael Prize is one of the most highly regarded international awards for the best contribution to scientific and clinical research which promote further developments in epileptology. Awarded biennially, it is specially designed to attract scientists not older than 45 years of age. Submission deadline: 31 December, 2016.
Prof. Elio Lugaresi passed away on December 22, 2015 in his 89th year. His passing leaves many in the neurologic community reflecting on his enormous legacy to the discipline. Elio Lugaresi's career was devoted to the study of neurology, neurophysiology, epilepsy, and above all sleep in all its aspects, a passion he pursued well into retirement.
Prof. Lugaresi was Ambassador for Epilepsy for the International League against Epilepsy from 1979, a corresponding member of the American Neurological Association and honorary Member of the Association for Sleep Disorders Centers, the German EEG Society, Société Française de Neurologie, Spanish League against Epilepsy, Italian Society of Sleep Medicine and the American Sleep Disorders Association.
When Hanneke de Boer died peacefully in her own home after a long illness faced with great dignity a light was extinguished on a life devoted to sufferers with epilepsy. Hanneke was one of the longest serving and greatest advocates of people with epilepsy of all ages, not only in her much loved country, The Netherlands, but across the world…
Enter the new photo competition for International Epilepsy Day 2016. The theme is "Yes, I can," to demonstrate achievement in overcoming obstacles, or achievement despite obstacles. The best photographs will form the International Epilepsy Day exhibition, taking place in the European Parliament in Strasbourg from Monday 1st to Friday 5th February 2016. All entries will also be placed in a gallery on the International Epilepsy Day website www.epilepsy.org.
Winners will receive US $1,000, and will be awarded in two categories: Photos taken with regular cameras, and photos taken with smartphones or tablets. All photos must be of high resolution; should reflect "the feeling of achievement;" and must include the hashtag #epilepsyday in some way. Read complete competition rules and guidelines.
DEADLINE FOR ENTRIES EXTENDED TO 17 January 2016
SUDEP Awareness Day was created by UK charity SUDEP Action and is dedicated to raising awareness of SUDEP all around the world. It was launched last year and was supported by 45 epilepsy organisations from around the world. SUDEP Awareness Day is celebrated annually on 23 October.
The day is aimed at:
World Stroke Day is on Thursday the 29th October 2015. The World Stroke Organization's theme for World Stroke Day 2015 is "I am Woman." The World Stroke Organization is calling on communities and individuals to use World Stroke Day to show they care. Share information about stroke prevention and ask the women in your community and your life to have a health check to avoid preventable stroke and cardiovascular disease.
This book presents a methodology for identifying and classifying lusters of risks that lead to SUDEP. Developed over the last two years, the SUDEP Classification System and Risk Factor Cluster ID method will help to address gaps in our knowledge about the causes and possible prevention of this tragic complication.
Edited by: Claire M. Lathers, Paul L. Schraeder, Jan E. Leestma, Braxton B. Wannamaker, Richard L. Verrier, Steven C Schachter, M.D.
A reference book on diagnosis, consequences, and management of neonatal and infantile seizures. This book provides new insights on how it is best to approach seizures and epilepsy in the first two years of life, to systematically create a blueprint upon which diagnostic and treatment decisions can be based.
Edited by: Helen Cross, Linda de Vries, Solomon Moshé, Douglas Nordli, Federico Vigevano
The Epilepsy Brain Bank at the College of Medicine at the University of Saskatchewan is one of the first epilepsy-centric brain banks in Canada, and the first focused solely on adult epilepsy research. It was established by a team led by Dr José Tellez-Zenteno, Dr. Farzad Moien-Afshari, Dr. Adam Wu and Dr. Lizbeth Hernandez-Ronquillo.
The epilepsy community lost a truly unique and powerful voice with the recent death of Karen Gale, Professor of Pharmacology at Georgetown University in Washington, D.C. and one of the founders and the director of the Georgetown Interdisciplinary Program in Neuroscience. Karen had a research agenda that was as wide as her active intellect, and she was best known for her examination subcortical circuitry, its pharmacological manipulation and how altering their activity affected behavior. Her pioneering research on the critical roles of subcortical structures, including the substantia nigra on seizure control and propagation has had a major role in our understanding of the distributed nature of seizures and how they might be controlled. Her more recent work on the comorbidities of epilepsy including deleterious effects of antiepileptic compounds on neural development has stimulated great discussion within the epilepsy community. Although Dr. Gale left an indelible mark as a researcher and educator, she is perhaps best known as a stalwart advocate for faculty, students and staff. She influenced and encouraged the careers and professional development off many junior colleagues. Read Karen Gale's obituary.
Innovative Medicines Initiative (IMI) 2 has just launched its 3rd call for proposals. The first topic on the call is titled RADAR: Remote Assessment of Disease and Relapse programme, which is exploring ways to ensure that the healthcare system moves from a ‘diagnose and treat’ stance to a ‘predict and pre-empt’ approach. The first application will be in CNS and epilepsy is specifically mentioned. Submission deadline: 24 March, 2015.
The Epilepsy Foundation is accepting entries in its 4th Annual Shark Tank competition, which seeks innovative ideas for epilepsy treatment and care. Finalists will present their ideas at the 2015 Antiepileptic Drug and Device Trials XIII, taking place May 13 to 15 in Aventura, Fla. The winner will receive up to $200,000 to advance his or her concept.
Letters of intent for the contest must be received by Feb. 16.
Additional grant and fellowship opportunities from the Epilepsy Foundation.
Report addressing burden and impact; challenges and gaps in care; international context and the Secretariat's activities; and improving epilepsy care: what is needed. The WHO Executive Board is invited to provide further guidance on the need for a coordinated action at the country level to address the health, social, and public knowledge implications of the global burden of epilepsy. Read report.
Elson So and Philippe Ryvlin have announced the publication of their new book, MRI-Negative Epilepsy, and are graciously donating the editors' royalties to the ILAE.
Drug-resistant epilepsy with negative MRI is frequently seen in patients considered for epilepsy surgery; however, clinical evaluation and surgical treatment is very complex and challenging. Overall, the outcome of MRI-negative surgery is less favorable than that of MRI-positive surgery, but it can significantly improve with optimal management.
Each chapter critically appraises the role and value of specific diagnostic and treatment techniques to address the challenges of MRI-negative epilepsy surgery. Authors critique evidence and share their expertise on the diagnostic options and surgical approaches that make epilepsy surgery possible and worthwhile in patients with this condition. Book summary, ordering information.
It is with great sadness that we announce the death of Professor Yukio Fukuyama, a true pioneer in the field of pediatric neurology who chaired the Department of Pediatrics at Tokyo Women’s Medical University, for a quarter of a century, teaching and mentoring young doctors and leading us into the 21st century. The depth and breadth of his accomplishments are a testament to his commitment to patients, their families, the university, his coworkers and advances in pediatric neurology worldwide. He will be sorely missed by friends and colleagues alike, thanks to his tireless efforts to advance Child Neurology, always based on his belief in “slow but steady” progress.
Ingrid Scheffer, past chair of the Classification and Terminology Commission of the ILAE, was appointed an Officer (AO) of the Order of Australia in the Queen's Birthday Honours List for distinguished service to medicine as a clinician, academic and mentor, and for research into identifying epilepsy syndromes and genes.
Prof Scheffer puts her success down to collaborating with a fantastic team, including Professor Sam Berkovic. Their work and research helped to uncover the first gene for epilepsy and to identify many of the known epilepsy genes from the human body's 25,000 genes.
“It means that patients all over the world can be diagnosed and their doctors can go looking for mutations of the genes,” she said. “Our work helps to figure out the best treatment and also can provide accurate genetic reproductive counselling.” Read article
The Vilcek Foundation is seeking applications for the 2015 Vilcek Prizes for Creative Promise in Biomedical Science. Three foreign-born biomedical scientists will be selected to receive the prizes, each including a cash award of $50,000. Researchers in all fields of biomedical science are encouraged to apply. Applicants must have been born abroad, be naturalized citizens or permanent residents of the United States, hold a doctoral degree, intend to pursue a career in the United States, and be no more than 38 years old as of December 31, 2014. In addition, they must also hold a full-time independent position at an academic institution or other organization.
H. Steven White, Ph.D., professor of pharmacology and toxicology and principal investigator of the National Institutes of Health-sponsored Anticonvulsant Drug Development (ADD) Program at the University of Utah College of Pharmacy, has been named the 2014 recipient of the Epilepsy Foundation's Lifetime Accelerator Award, in recognition of his commitment and pioneering contributions to the field of epilepsy and seizures. Dr. White will be honored at the 4th Biennial Epilepsy Pipeline Conference 2014, being held June 5-7, 2014, at the Hyatt Regency San Francisco.
The Lifetime Accelerator Award was established in 2012 to honor physicians, scientists, industry leaders, and other individuals who have demonstrated a lifelong commitment to bringing new therapies to people living with epilepsy. Recipients are chosen by an independent committee of global thought leaders and clinical investigators in epilepsy and seizure therapy discovery and development. More …
The idea of Therapeutic Patient Education (TPE) in France takes its roots in a desire of changing the approach to epilepsy care. Development of TPE started from the difficulties that patients and health care professionals are facing when trying to understand the objectives of Epilepsy treatments, often prescribed at the end of a very short visit. More than just counting seizures, prescribing drugs or discussing surgery, other individual factors (mood, behavior, self esteem), specific to each patient should be takeninto account. Indeed, teaching is most efficient with the involvement of the person the message is addressed to so that the patient can fully be part of the process… Read "Cahier" special issue (Français) | Summary (English)
The European Forum on Epilepsy Research (ERF2013) took place in Dublin from May 26-29, 2013. Its objective was to provide a platform on how to improve the lives of persons with epilepsy in Europe by influencing the future political agenda of the EU.
The ERF 2013 defined objectives and milestones for the epilepsy community 1) how to strengthen epilepsy research, 2) how to reduce the treatment gap, and 3) how to reduce the burden and stigma of epilepsy.
This joint declaration of the Japanese Epilepsy Society (JES) and the Japanese Bureau for Epilepsy (JEA) was prepared with hopes that it will be helpful for the improvement of the circumstance of people with epilepsy, not only in Japan but also over the world.
The Report on Epilepsy in Latin America and the Caribbean (2013) prepared by the Pan American Health Organization (PAHO/WHO) with the support of the International League against Epilepsy and the International Bureau for Epilepsy is now available.
EpiNet (www.epinet.co.nz), an international collaborative clinical epilepsy research project endorsed by the New Zealand Chapter, continues to seek participation from ILAE chapter members. Current studies include "What is a seizure," which is an online study designed to determine how consistently physicians interpret case histories. It involves 32 case histories with different clinical presentations. Everyone who completes the 32 cases before the end of March 2014 will go into the draw to win a holiday of a lifetime in New Zealand.
EpiNet comprises a secure patient database, into which doctors can enter details on any person with epilepsy. It can be used by doctors from any country, provided they get approval from their IRB or other relevant authority. Currently, there are over 5,000 patients in the EpiNet database. Patients have been registered from 20 countries. The platform has been created to facilitate investigator-led research, and in particular to perform simple, multi-centre, pragmatic randomised controlled trials.
The Clinique d’Épilepsie de Port-Au-Prince (CLIDEP), which opened its doors in 2008 with the help of the North American Commission of the ILAE now has a secondary site in rural Haiti.
With the help of the Rotary Foundation, the North American Commission was able to obtain a vehicle to perform on a bi-monthly basis mobile clinics in the region of the Central Plateau, more precisely in the cities of Saint-Marc and Cange. … more
The Michael Prize is one of the most highly regarded international awards for the best contribution to scientific and clinical research which promote further developments in epileptology. Awarded biennially, it is specially designed to attract scientists not older than 45 years of age. Submission deadline: 31 December, 2014.
IBE and ILAE were honoured to have EU Commissioner Tonio Borg launch European Epilepsy Day 2014 at a reception in the European Parliament in Strasbourg on 4th February.
European Union Commission Website: http://ec.europa.eu/commission_2010-2014/borg/index_en.htm
Heung Dong Kim,,
Hoon-Chul Kang, Sang Ahm Lee, Kyun Huh, Byung-In Lee
Epilepsia. Article first published online: 13 JAN 2014. DOI: 10.1111/epi.12516
Public misconception of epilepsy may lead to significant stigma to the disease itself, thereby causing impaired quality of life in people with epilepsy. Traditionally, epilepsy has been considered to be the consequence of evanescent spiritual forces, and even demonic possession (in many countries). The names of epilepsy in some East Asian countries originated from China, and include madness in their meaning. We recently changed the Korean name of epilepsy, gan-jil (간질, 癎疾: a crazy, convulsive disease having meaning similar to 癲癎), to a neutral and scientifically explainable name: noi-jeon-jeung (뇌전증; 腦電症; cerebroelectric disorder). We expect that changing the stigmatized name of epilepsy to a neutral and scientific term with the meaning of cerebroelectric disorder will reduce the social stigma by understanding of epilepsy as one of the neurologic disorders.
John M. Freeman, MD, an internationally renowned Johns Hopkins pediatric neurologist and medical ethicist whose iconoclastic questioning of established medical practices revolutionized the treatment of pediatric epilepsy and advanced the development of modern biomedical ethics, died on Friday, Jan. 3, 2014 of cardiovascular disease. He was 80.
LD and Epilepsy Review
Volume 2, Issue 8, Summer 2013
Two articles approach areas of great importance in care delivery; two others approach common clinic issues.
This publication contains a lot of useful information for people with epilepsy:
... and more.
New Award: Epilepsy Innovation Seal of Excellence - Application deadline 21 August, 2013
The Epilepsy Foundation, a national organization dedicated to serving all people with seizures, launched the Epilepsy Innovation Seal of Excellence (SEAL), an award that recognizes groundbreaking and innovative product development programs deemed by the Foundation as deserving of significant and urgent support. The launch of the SEAL is part of the Foundation’s strategic mandate to recognize critical advancements in the field of epilepsy. The SEAL is designed to facilitate access to funding and resources that will carry the recipient’s work through proof of concept and beyond, which typically costs from $1 million to $5 million dollars.
Professor Shunsuke Ohtahara passed away early in the morning of March 16, 2013, at the age of 83. He was well known in the academic world for the disease that he first described and which was named after him: Ohtahara syndrome.
See tribute by Prof Ohtsuka and photographs.
The epilepsy and neurology communities at large mourn the loss of our colleague, Dr. Eli S. Goldensohn who passed away on March 22, 2013 at the age of 98. During his long career, he was Professor of Neurology at the College of Physicians & Surgeons at Columbia University as well as at the Albert Einstein College of Medicine; President of the American Epilepsy Society, the American EEG Society, the Eastern EEG Society and Chair of the Professional Advisory Board of the Epilepsy Foundation of America...
See tribute by Nico Moshé and Tim Pedley
Jerome H. Chin, MD, PhD, MPH
Neurology February 19, 2013 vol. 80 no. 8 754-755 doi: 10.1212/WNL.0b013e31828250c5
There are an estimated 50 million people living with epilepsy (PLWE) worldwide. In the United States and other high-income countries, PLWE are offered a wide range of advanced diagnostic and therapeutic services. In stark contrast, the vast majority of PLWE in poorer regions of the world receive no care and treatment...
Joseph Roger passed away on September 3, 2012, in his 94th year. He was a major epileptologist of his time, the founder of a school with pupils from all over the world, and had a remarkable personality …
See tribute by Charlotte Dravet and colleagues
This forum is a collaborative research conference co-funded by the 7th Framework Programme of the European Commission in conjunction with the Irish Presidency of the European Union in 2013 and the European month of the Brain, May, 2013. It aims to bring together leading epilepsy researchers and policy makers in Europe to discuss a coordinated strategy for epilepsy research into the future. The three main objectives are:
The programme comprises the following six main topics, along with a number of innovative additional sessions, including "How to Make Your Voice Heard in the EU."
Visit the Conference site for complete information and to register.
Dr. Warren Blume has been appointed as a Member of the Order of Canada for his long and distinguished service to Canadian citizens who suffer from epilepsy. The award recognizes his lifelong dedication to improving the lives of people with epilepsy, especially in the underserved areas of Ontario, service that was also recently recognized with the Kiffin Penry Award from the American Epilepsy Society.
Dr. Blume is Professor of Neurology Emeritus at the University of Western Ontario in London, where he began his career in 1972. In 1977 he helped establish the first epilepsy program in Ontario and the second in Canada. He is known around the world for his atlases in electroencephalography, which have contributed greatly to the training of several generations of electroencephalographers and epileptologists as well as for his numerous publications that have provided new insights into the clinical pathophysiology of epilepsy. He was one of the founding members of the Canadian League Against Epilepsy and was a leader in creating the EEG certification examination in Canada
The Order of Canada was established in 1967, Canada's centennial year by Queen Elizabeth II. It is the centerpiece of Canada's honors system and is one of the country's highest civilian awards. Election as a Member recognizes a lifetime of outstanding achievement, dedication to the community and service to the nation.
The latest newsletter from the Commission on Asian and Oceanian Affairs (CAOA) features a summary of the 9th Asian Oceanian Epilepsy Congress, held in Manila, The Philippines in 2012.
Other articles include reports from Australia, India, Japan, Korea, Sri Lanka, Taiwan, Thailand, as well as a report on EpiNet, the AOEO Chapter List, and the list of CAOA officers and members.
Jack J Lin, MD; Marco Mula, MD; Bruce P Hermann, Ph.D.
The Lancet, Volume 380, Issue 9848, Pages 1180 - 1192, 29 September 2012 doi:10.1016/S0140-6736(12)61455-X
In this report we define the specific psychiatric, cognitive, and social comorbidities of paediatric and adult epilepsy, their epidemiology, and real life effects; examine the relation between epilepsy syndromes and the risk of neurobehavioural comorbidities; address the lifespan effect of epilepsy on brain neurodevelopment and brain ageing and the risk of neurobehavioural comorbidities; consider the overarching effect of broader brain disorders on both epilepsy and neurobehavioural comorbidities; examine directions of causality and the contribution of selected epilepsy-related characteristics; and outline clinic-friendly screening approaches for these problems and recommended pharmacological, behavioural, and educational interventions.
The 6th annual Baltic Sea Summer Schools on Epilepsy (BSSSE) held in Rostock (Germany, July 8-13, 2012) was attended by 40 postgraduate students from Africa, Asia/Oceania, Eastern Mediterranean, Europe and Latin America. The course was co-directed by ILAE Past President Peter Wolf, Denmark, and ILAE Educational Commission member RÃ¼diger KÃ¶hling, Germany, with Ruta MameniÅ¡kiene, President of the Lithuanian ILAE chapter, as programme coordinator.
The course format is strongly interactive. Frontal teaching at the BSSSE is reduced to a few introductory lectures and tutorials in groups of changing composition, and included morning “cappuccino sessions,” case studies and peer to peer group discussions.
Latest newsletter from the African Commission. Read a recap of the First African Epilepsy Congress, held in Nairobi in June, 2012. This issue also includes a first-hand account of a person living with epilepsy; Nigerian League Against Epilepsy (NLAE) Conference reports; the story of Kenya Association for the Welfare of People with Epilepsy (KAWE); and calendars of coming events.
An Act representing a day to increase public awareness about epilepsy, Bill C-278, has received Royal Assent and is now a legally recognized day for epilepsy awareness in Canada. The Bill establishes March 26 as Purple Day, a day each year when Canadians wear purple to promote a greater awareness of epilepsy and support the 300,000 Canadians living with the disorder.
Purple Day for Epilepsy is celebrated each year on March 26 and is dedicated to raising awareness about epilepsy. It helps reduce stigma and empowers individuals living with epilepsy to take action in their communities. Purple Day was founded in 2008 by nine-year-old Cassidy Megan of Nova Scotia, and named after the internationally recognized colour for epilepsy, lavender. Purple Day was launched internationally in 2009. The Epilepsy Association of Nova Scotia and the Anita Kaufmann Foundation in the United States are the Global Partners for the Purple Day Campaign.
Ernst Niedermeyer died on April 5, after nearly 2 years with colon cancer, borne with grace and faith, but with pain in the final weeks. His teaching and lectures, his interests in clinical electroencephalography in general and in electroencephalographers and neurodiagnostic technologists in particular, and his over 240 publications, including the textbook he edited for many years and through many editions, Electroencephalography – Basic Principles, Clinical Applications and Related Fields, made him perhaps the most famous electroencephalographer in the world.
The Michael Prize is awarded biennially and is specially designed to attract younger scientists (normally not older than 45 years of age). Applications are now being accepted for the 2013 Michael Prize. Read requirements announcement.
US Institute of Medicine (IOM) Report
The Institute of Medicine report addresses the many obstacles faced by people with epilepsy and their caregivers in obtaining the necessary care. Although the report was written to address the situation in the United States, a quick review of the findings show that the recommendations can be applied in most countries. It provides a thorough and objective overview of the problems and a means to identify the issues that will require solutions, thus serving as a starting point for planning at the national and regional level. View video and report.
Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society
C.Y. Go, MD, M.T. Mackay, MBBS, FRACP, S.K. Weiss, MD, FRCPC, D. Stephens, MSc, T. Adams-Webber, MLS, S. Ashwal, MD, FAAN and O.C. Snead III, MD FAAN
Neurology, 2012;78;1974; DOI 10.1212/WNL.0b013e318259e2cf
Objective: To update the 2004 American Academy of Neurology/Child Neurology Society practice parameter on treatment of infantile spasms in children.
Recommendations: Low-dose ACTH should be considered for treatment of infantile spasms. ACTH or VGB may be useful for short-term treatment of infantile spasms, with ACTH considered preferentially over VGB. Hormonal therapy (ACTH or prednisolone) may be considered for use in preference to VGB in infants with cryptogenic infantile spasms, to possibly improve developmental outcome. A shorter lag time to treatment of infantile spasms with either hormonal therapy or VGB possibly improves long-term developmental outcomes.
Carl Zimmer; Discover Magazine; June 2012 issue; published online May 15, 2012.
Hidden Epidemic: Tapeworms Living Inside People's Brains. Parasitic worms leave millions of victims paralyzed, epileptic, or worse. So why isn't anyone mobilizing to eradicate them? View article
Dr. Carlos Acevedo (PAHO) and Dr. Emilio Perucca (European Declaration) provide a discussion of current status of these initiatives. View videos.
First newsletter of the African Commission. Topics include First African Epilepsy Congress, Nairobi, 2012; Africans in Diaspora; My Personal Experience: Living with Epilepsy; Chapter Congresses; Education and Epilepsy. Read EpilepsyNews Africa.
Considering that the number of neurologists in Bolivia is much lower than the rate per capita recommended by the WHO, we believe that it is essential to provide the basic tools for the diagnosis and treatment of neurological disorders to primary care physicians and family doctors. For the above reasons we decided to provide training on basic concepts of methodology and epidemiology and on the most frequent neurological diseases such as stroke, epilepsy, dementia, headache, and central nervous system infections. Read report
The World Federation of Neurology invites project proposals for specific educational or applied research projects in neurology and the applied neurosciences as part of its activities as a registered charitable organization and its mission to "foster quality neurology and brain health worldwide." The President of ILAE will be part of the project selection committee. More information...
Ingrid Scheffer, Professor of Medicine and Pediatrics and Chair of Pediatric Neurology Research at the University of Melbourne, is one of the five recipients of the 2012 L'Oréal-UNESCO Women in Science Awards. The award, which includes a $100,000 prize will be formally presented at UNESCO Headquarters in Paris in March, 2012. Read more
Washington, D.C., 29 September 2011 – The countries of the Americas, with support from the Pan American Health Organization/World Health Organization (PAHO/WHO), will work together to create national programs for the care and treatment of epilepsy, a neurological disorder that affects some 5 million people in the Americas.
A Written Declaration on Epilepsy was passed in the European Parliament yesterday, 15th September 2011. Submitted by the European Advocates for Epilepsy Working Group in collaboration with Epilepsy Advocacy Europe – a joint task force of the International League Against Epilepsy and the International Bureau for Epilepsy, approval of the declaration marks a significant step in the efforts of both groups to increase the quality of life of people with epilepsy. Read complete news release
The law for protecting the rights of people with epilepsy came into force in Colombia November 11, 2010. The effort to create this law began 40 years ago, and the initiative was first met with indifference and inaction. The Colombian League Against Epilepsy found a champion in Senator Manuel Virgũez who assisted in the writing of the law and led it through the complex legislative process. The law went into effect after the Constitutional Court of Colombia ruled that the law was constitutional, citing that people with epilepsy needed enhanced legal protection. The law is placed on the web site to provide an example of how such laws can be written and of the many issues and roadblocks that are faced by people with epilepsy.
The following is copied from the Institute of Medicine (IOM) web site
“The IOM is undertaking a new study that will consider the public health dimensions of the epilepsies in the United States—including health care and human services, health literacy, and education. The IOM will recommend priorities in these areas in order to better understand the public health impact of the epilepsies and to meet the needs of people with epilepsy and their caregivers. Specifically, the IOM will focus on the following questions:
- How can the public health burden of epilepsy for patients and families be more accurately assessed?
- What priorities for future population health studies could inform treatment and prevention?
- How can the access to health and human services and the quality of care for people with epilepsy be improved?
- How can the education and training of professionals who work with people with epilepsy be improved?
- How can the understanding of epilepsy in patients and the general public be improved to create supportive communities?"
The international community of epilepsy specialists is providing financial support and specialized medical equipment contributed by its manufacturer to help re-establish services to epilepsy patients in Haiti halted by the devastating earthquake. Read more
Fundamentals on epilepsy: Neurobiological, clinical and therapeutic approaches.
Sunlodge Hotel, Accra, Ghana - January 16 – 22, 2010. Read more
With kind permission of the World Federation of Neurology we are please to make available to you a publication from the WFN's Seminars in Clinical Neurology series "Epilepsy: Global Issues for the Practicing Neurologist." This publication was chaired by Jerome Engel of the University of California at Los Angeles with a panel of international experts. The focus is on issues that are more commonly faced in the developing world, but this book also has broader application. You can find this publication on the web site of the WFN (www.wfneurology.org). The WFN site also has other publications in the Clinical Neurology series that you may find of interest. Read more
The EU Clinical Trials Registry was launched today by the European Medicines Agency (EMA). The online register gives for the first time public access to information on interventional clinical trials for medicines authorised in the 27 EU Member States and Iceland, Liechtenstein and Norway. The database also allows the public to search for information on clinical trials authorised to be carried out outside the EU if these trials are part of a paediatric investigation plan.
Full News Release
EU Clinical Trials Registry